Cargando…

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, Patrick, Woodhall, Mark, O'Connor, Kevin C., Reindl, Markus, Lang, Bethan, Sato, Douglas K., Juryńczyk, Maciej, Tackley, George, Rocha, Joao, Takahashi, Toshiyuki, Misu, Tatsuro, Nakashima, Ichiro, Palace, Jacqueline, Fujihara, Kazuo, Leite, M. Isabel, Vincent, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370386/
https://www.ncbi.nlm.nih.gov/pubmed/25821844
http://dx.doi.org/10.1212/NXI.0000000000000089
_version_ 1782362863151611904
author Waters, Patrick
Woodhall, Mark
O'Connor, Kevin C.
Reindl, Markus
Lang, Bethan
Sato, Douglas K.
Juryńczyk, Maciej
Tackley, George
Rocha, Joao
Takahashi, Toshiyuki
Misu, Tatsuro
Nakashima, Ichiro
Palace, Jacqueline
Fujihara, Kazuo
Leite, M. Isabel
Vincent, Angela
author_facet Waters, Patrick
Woodhall, Mark
O'Connor, Kevin C.
Reindl, Markus
Lang, Bethan
Sato, Douglas K.
Juryńczyk, Maciej
Tackley, George
Rocha, Joao
Takahashi, Toshiyuki
Misu, Tatsuro
Nakashima, Ichiro
Palace, Jacqueline
Fujihara, Kazuo
Leite, M. Isabel
Vincent, Angela
author_sort Waters, Patrick
collection PubMed
description OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG (FL-MOG) or the short-length form (SL-MOG). The Abs were initially detected by Alexa Fluor goat anti-human IgG (H + L) and subsequently by Alexa Fluor mouse antibodies to human IgG1. RESULTS: When tested at 1:20 dilution, 40/1,109 sera were positive for AQP4-Abs, 21 for SL-MOG, and 180 for FL-MOG. Only one of the 40 AQP4-Ab–positive sera was positive for SL-MOG-Abs, but 10 (25%) were positive for FL-MOG-Abs (p = 0.0069). Of equal concern, 48% (42/88) of sera from controls (patients with epilepsy) were positive by FL-MOG assay. However, using an IgG1-specific secondary antibody, only 65/1,109 (5.8%) sera were positive on FL-MOG, and AQP4-Ab– positive and control sera were negative. IgM reactivity accounted for the remaining anti-human IgG (H + L) positivity toward FL-MOG. The clinical diagnoses were obtained in 33 FL-MOG–positive patients, blinded to the antibody data. IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1). All 7 patients with probable multiple sclerosis (MS) were MOG-IgG1 negative. CONCLUSIONS: The limited disease specificity of FL-MOG-Abs identified using Alexa Fluor goat anti-human IgG (H + L) is due in part to detection of IgM-Abs. Use of the FL-MOG and restricting to IgG1-Abs substantially improves specificity for non-MS demyelinating diseases. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of serum IgG1- MOG-Abs in AQP4-Ab–negative patients distinguishes non-MS CNS demyelinating disorders from MS (sensitivity 24%, 95% confidence interval [CI] 9%–45%; specificity 100%, 95% CI 88%–100%).
format Online
Article
Text
id pubmed-4370386
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-43703862015-03-27 MOG cell-based assay detects non-MS patients with inflammatory neurologic disease Waters, Patrick Woodhall, Mark O'Connor, Kevin C. Reindl, Markus Lang, Bethan Sato, Douglas K. Juryńczyk, Maciej Tackley, George Rocha, Joao Takahashi, Toshiyuki Misu, Tatsuro Nakashima, Ichiro Palace, Jacqueline Fujihara, Kazuo Leite, M. Isabel Vincent, Angela Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG (FL-MOG) or the short-length form (SL-MOG). The Abs were initially detected by Alexa Fluor goat anti-human IgG (H + L) and subsequently by Alexa Fluor mouse antibodies to human IgG1. RESULTS: When tested at 1:20 dilution, 40/1,109 sera were positive for AQP4-Abs, 21 for SL-MOG, and 180 for FL-MOG. Only one of the 40 AQP4-Ab–positive sera was positive for SL-MOG-Abs, but 10 (25%) were positive for FL-MOG-Abs (p = 0.0069). Of equal concern, 48% (42/88) of sera from controls (patients with epilepsy) were positive by FL-MOG assay. However, using an IgG1-specific secondary antibody, only 65/1,109 (5.8%) sera were positive on FL-MOG, and AQP4-Ab– positive and control sera were negative. IgM reactivity accounted for the remaining anti-human IgG (H + L) positivity toward FL-MOG. The clinical diagnoses were obtained in 33 FL-MOG–positive patients, blinded to the antibody data. IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1). All 7 patients with probable multiple sclerosis (MS) were MOG-IgG1 negative. CONCLUSIONS: The limited disease specificity of FL-MOG-Abs identified using Alexa Fluor goat anti-human IgG (H + L) is due in part to detection of IgM-Abs. Use of the FL-MOG and restricting to IgG1-Abs substantially improves specificity for non-MS demyelinating diseases. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of serum IgG1- MOG-Abs in AQP4-Ab–negative patients distinguishes non-MS CNS demyelinating disorders from MS (sensitivity 24%, 95% confidence interval [CI] 9%–45%; specificity 100%, 95% CI 88%–100%). Lippincott Williams & Wilkins 2015-03-19 /pmc/articles/PMC4370386/ /pubmed/25821844 http://dx.doi.org/10.1212/NXI.0000000000000089 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Article
Waters, Patrick
Woodhall, Mark
O'Connor, Kevin C.
Reindl, Markus
Lang, Bethan
Sato, Douglas K.
Juryńczyk, Maciej
Tackley, George
Rocha, Joao
Takahashi, Toshiyuki
Misu, Tatsuro
Nakashima, Ichiro
Palace, Jacqueline
Fujihara, Kazuo
Leite, M. Isabel
Vincent, Angela
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title_full MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title_fullStr MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title_full_unstemmed MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title_short MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
title_sort mog cell-based assay detects non-ms patients with inflammatory neurologic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370386/
https://www.ncbi.nlm.nih.gov/pubmed/25821844
http://dx.doi.org/10.1212/NXI.0000000000000089
work_keys_str_mv AT waterspatrick mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT woodhallmark mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT oconnorkevinc mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT reindlmarkus mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT langbethan mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT satodouglask mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT jurynczykmaciej mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT tackleygeorge mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT rochajoao mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT takahashitoshiyuki mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT misutatsuro mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT nakashimaichiro mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT palacejacqueline mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT fujiharakazuo mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT leitemisabel mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease
AT vincentangela mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease